Peer-reviewed article
2529. Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations with 24-Month Growth and Neurodevelopment
Moraka N, Moyo S, Ibrahim M, Mayondi G, Leidner J et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study examined whether cytomegalovirus (CMV) infection is associated with poor growth and neurodevelopment in Botswana children aged 24 months, comparing HIV-exposed uninfected children with HIV-unexposed uninfected children. Among 317 children tested, 67.8% had positive CMV serology at 18 months, with higher rates among HIV-unexposed children. The research found that CMV status was not associated with child growth measurements or neurodevelopmental outcomes on standardized tests at 24 months.
Key points
- 67.8% of children tested positive for CMV antibodies at 18 months
- HIV-unexposed uninfected children had significantly higher CMV seropositivity (82.6%) compared with HIV-exposed uninfected children (47.4%)
- Breastfeeding likely explains higher CMV rates in unexposed children (96.7% of HUU vs 10.5% of HEU children breastfed)
- CMV status showed no association with growth measures (head circumference, weight-for-age, weight-for-height, height-for-age) at 24 months
- CMV status showed no association with neurodevelopmental domains (receptive and expressive language, fine and gross motor, cognitive) on Bayley Scales at 24 months
Limitations
This is an observational study using existing data and samples, so causation cannot be inferred. The study does not explain why HIV-exposed uninfected children have poorer growth outcomes if CMV status is not responsible, leaving the underlying mechanisms unresolved.
Abstract
Abstract Background HIV-exposed but uninfected (HEU) children are at increased risk for poorer growth outcomes compared with HIV-unexposed/uninfected (HUU) children. Mechanisms underlying the poorer growth and delays in development of HEU children compared HUU children are not fully understood. We sought to define the relationship between child CMV status and HIV− exposure status and determine if a correlation existed between CMV status and growth (and neurodevelopmental) outcomes by 24 months of age in Botswana. Methods We used existing data and samples from the observational Botswana Tshipidi study, pregnant women living with HIV (WLHIV) and those without HIV, as well as their infants were enrolled and followed prospectively through 2 years postpartum. We tested 18-month child plasma samples from all available children for anti-HCMV IgG. We evaluated the association between positive (vs. negative) child CMV status at 18 months, and child growth, using the World Health Organization’s Growth Standard adjusted for age and sex and neurodevelopment at 24 months of age, using the Bayley Scales of Child Development (BSID) III. Results Of 317 children tested for CMV IgG at 18 months, 215 (67.8%) tested positive. Significantly higher proportions of HUU children had positive CMV serology (82.6%) compared with HEU children (47.4%, P < 0.01); 96.7% of HUU vs. 10.5% of HEU children breastfed. Child CMV infection was not associated with head circumference, weight-for-age, weight-for-height, nor height-for-age z-scores at 24 months. BSID III scores in receptive and expressive language, fine and gross motor, and cognitive domains at 24 months of age also did not differ by child CMV status. Conclusion We observed high rates of CMV seropositivity in 18-month-old children in Botswana with significantly higher CMV seropositivity among HUU children likely owing to breastfeeding. Positive CMV serostatus was not associated with child growth or neurodevelopmental outcomes at 24 months. Disclosures All authors: No reported disclosures.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Study examining whether CMV infection explains growth and neurodevelopmental outcomes
- Population
- 317 children in Botswana followed prospectively from pregnancy through 24 months; subgroups of HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU) children
Key finding
CMV seropositivity at 18 months: 67.8% overall, 82.6% HUU, 47.4% HEU (p<0.01)